semaj83/ctmatch_classification huggingface dataset:
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  PMDD PMS Depression The subjects of this study will be women who meet the for MRMD as described in Protocol No. 81-M-0126, 'The Phenomenology and Biophysiology of Menstrually-related Mood and Behavioral Disorders.' In brief, these history within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress symptoms should have a sudden onset and offset age 18-50 not pregnant and in good medical health medication free All patients participating in this protocol will have already participated in Protocol No. 81-M-0126 and will have a prospectively confirmed and predictable relationship between their mood disorder and the premenstrual phase of the menstrual cycle, i.e., a 30% change in severity of symptom self rating scales, relative to the range of the scale employed, during the seven days premenstrually compared with the seven days post-menstrually in two out of three months of study The Schedule for Affective Disorders and Schizophrenia will be administered to all patients prior to study entry. Any patient with a current axis I psychiatric diagnosis will be excluded from participating in this protocol Prior to treatment, a complete physical and neurological examination will have been performed and the following routine laboratory data obtained A. Blood  The following conditions will constitute contraindications to treatment with hormonal therapy and will preclude a subject's participation in this protocol current Axis I psychiatric diagnosis history consistent with endometriosis diagnosis of ill-defined, obscure pelvic lesions, particularly, undiagnosed ovarian enlargement hepatic disease as manifested by abnormal liver function tests history of mammary carcinoma history of pulmonary embolism or phlebothrombosis undiagnosed vaginal bleeding porphyria diabetes mellitus
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Porphyria ENTRY --Disease Characteristics- Acute porphyria, i.e.: Acute intermittent porphyria Hereditary coproporphyria Variegate porphyria Definite cyclic attacks with severe abdominal pain and other porphyria symptoms during luteal phase of menstrual cycle only Attacks resolve completely within 5 days of onset of menses, i.e., no symptoms between attacks At least 4 to 6 attacks during the 6 months prior to entry More than half of these attacks must meet the following Readily distinguishable from menstrual cramps and premenstrual syndrome Required hospitalization for narcotic analgesics, phenothiazines, hematin, intravenous fluids, or other treatment Luteal attacks not requiring hospitalization must be similar in symptoms and differ only in severity No life-threatening porphyria attacks No cyclic abdominal pain unless caused by porphyria --Prior/Concurrent Therapy- At least 6 months since ovulation suppression --Patient Characteristics- Reproductive: Menstrual cycle 25-35 days for at least 6 months prior to entry Pelvic exam normal within 60 days prior to entry Pap smear normal, i.e., no dysplasia No amenorrhea No other menstrual abnormality No other gynecologic abnormality Negative pregnancy test Medically approved contraception required for 2 months prior to entry and throughout study OR at least 1 menstrual cycle following tubal ligation Other: No allergy to gonadotropin-releasing hormone analogues No clinically significant abnormal laboratory test results No medical contraindication to protocol treatment
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Amphetamine-Related Disorders years of age. Treatment seeking for meth dependence  Please contact site director for more details
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Endometrial Bleeding Periodontal Disease Regular menstrual periods for the last 2 cycles Currently not using hormonal contraceptives, including oral contraceptives, patch, ring, or Norplant in 2 months prior to study entry, or Depo-Provera in 12 months prior to study entry Currently not using tetracycline-class antibiotics Normal Pap smear  Pregnancy or breastfeeding within 2 months of study entry Chronic migraine headaches Uncontrolled high blood pressure Untreated sexually transmitted diseases Alcoholism or drug abuse within 12 months of study entry Insulin dependent diabetes Liver, kidney, or gallbladder disease Participation in another clinical trial within 30 days of study entry History of cancer History of blood clots, strokes, or heart disease
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Endometriosis Female patients with endometriosis-associated pelvic pain  Pregnant or lactating women history or suspicion of hormone dependent tumor therapy resistant endometriosis need for primary surgical treatment any other conditions which forbid the participation
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 25.0-50.0,  Leiomyoma Female gender-to evaluate effects in the target population for clinical trials History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as defined by the American College of Obstetrics and Gynecology (ACOG) practice bulletin Excessive uterine bleeding will be evidenced by either of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection Uterine leiomyoma(ta) of at least 2 cm size In good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at the discretion of the research team. Interval use of over-the-counter drugs is acceptable but must be recorded Menstrual cycles of 24 days Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered to improve red blood cell counts Willing and able to comply with study requirements  Significant abnormalities in the history, physical or laboratory examination Pregnancy Lactation Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year Unexplained vaginal bleeding History of malignancy within the past 5 years Use of estrogen or progesterone-containing compounds, such as oral contraceptives and hormone replacement therapy, within 8 weeks of study entry, including transdermal, injectable, vaginal and oral preparations Use of agents known to induce hepatic P450 enzymes; use of imidazoles Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that affect menstrual cyclicity Follicle stimulating hormone (FSH) greater than 20 IU/mL
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Menopause Insomnia Women 40+ years old Subject must have any of the following perimenopausal or postmenopausal signs and symptoms as defined by the Stages of Reproductive Aging Workshop (STRAW) Early Menopausal Transition (Stage -2): Variable cycle length >7 days different from normal Late Menopausal Transition (Stage -1) : > 2 skipped cycles and an interval of amenorrhea > 60 days Post Menopause (Stage +1): Amenorrhea for at least 12 months Surgical Post Menopause Hysterectomized women with one or both ovaries preserved will be eligible if FSH levels > 20 IU/L If on hormonal therapy, history of menstrual-cycle abnormalities consistent with any of 2a-2e above indicating peri-/postmenopausal status prior to initiation of hormonal therapy One or both the following insomnia symptoms for ³ 3 nights per week for at least one month prior to study enrollment Difficulty initiating sleep (³ 30 minutes)  According to M.I.N.I (Mini International Neuropsychiatric Interview), subject meets current or past for past 3 months Major Depression Dysthymia Panic disorder PTSD (Post-Traumatic Stress Disorder) According to M.I.N.I, subject has no evidence of current suicidal ideation, homicidal ideation, or psychotic symptoms at screening visit Suicide attempt in the past 5 years According to M.I.N.I, subject meets for substance use disorder diagnosis within the past 5 years Subject has current or recent use (in the past month and used > 25% of time) of hypnotic agents Subject is on an antidepressant or hormone therapy in past 2 months. (Unless they are taking currently and have had a stable dose for ≥ 2 months)
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Dysmenorrhea Patients aged 20 years or older at obtaining informed consent Patients having the normal menstrual cycle (25 to 38 days) in the latest two menses before the final enrollment Patients having a total dysmenorrheal score of at least 3 points in twice of the latest menstruation before the final enrollment  Patients with ovarian chocolate cysts Patients with fibroid needed to be treated Patients with estrogen-dependent tumors and patients with cervical cancer or suspected cervical cancer Patients with undiagnosed abnormal vaginal bleeding Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease, or coronary artery disease or a history of those diseases Patients aged 35 years or older who smoke at least 15 cigarettes per day Patients with migraine accompanied by prodromata Patients with pulmonary hypertension or valvular heart disease Patients who are regularly taking nutritional products that contain St. John's Wort Patients who underwent surgical treatment for endometriosis within 2 months prior to screening
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Bipolar Disorder Ages 18-45 Bipolar Disorder (BD) I or II (DSM-IV criteria) must agrees to communication between PI and Psychiatrist Healthy Control without Past or Current Major Depression, Psychotic Disorder, premenstrual syndrome or Premenstrual Dysphoric Disorder 31day menstrual cycles Minimum 6 menstrual cycles per year  Current DSM-IV Alcohol or Substance Abuse/Dependence Pregnancy Chronic Anovulation (<4 menstrual cycles/yr) Menopause (< 1menses in 1yr) Active thyroid disease Hormonal Contraception
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Breast Pain Premenstrual mastalgia Age 20-45 years Reliable non-hormonal contraception  Pregnancy Breast cancer or uterine corpus cancer Unexplained menstrual disorders Serious health problems Hormonal contraception, including hormonal IUD trade name Mirena Oestrogen and/or progestin treatment Hysterectomy and/or oophorectomy or radiation therapy Artificial cardiac pacemaker/metallic prostheses
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  ADHD Trichotillomania DSM-IV Diagnosis of trichotillomania DSM-IV diagnosis of ADHD Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to entering the study  History of moderate or severe adverse event, related to MPH History of any psychotic disorder Current drug abuse, acute psychotic or affective disorder
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metrorrhagia Women age 18 or older who are initiating Depo-Provera for contraception English or Spanish-speaking Have a negative urine pregnancy test  Contraindications to either Depo-Provera or Femring (estrogen vaginal ring) Have used Depo-Provera or Mirena in the prior 6 months Have had an induced abortion, spontaneous abortion, or birth in prior 8 weeks
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-48.0,  Premenstrual Syndrome Meets DSM-IV for PMDD by history Regular menstrual cycles that are 25 to 35 days in length during the year prior to study entry Willing to use barrier methods of birth control during the study if sexually active If engaged in psychotherapy for at least 3 months before study entry, participation will be allowed if the intensity of psychotherapy remains the same during the study Normal PAP and physical exam, including pelvic exam, within the 1 year prior to study entry  Use of oral contraceptives or other exogenous hormone preparations within the 3 months prior to study entry Suicide attempt or severe suicidal ideation within the 2 years prior to study entry History of any psychotic disorder or bipolar disorder Substance abuse, except nicotine, within the 6 months prior to study entry Use of pharmacological treatment for PMDD symptoms (e.g., antidepressants, hormones, gonadotropin-releasing hormone agonists, anxiolytics, calcium, herbal preparations, diuretics) within the 3 months prior to study entry Daily use of psychotropic or anticonvulsant medications within the 3 months prior to study entry Use of sleeping pills more than once per week Consumption of more than 50 ounces of alcohol per week Pregnant or breastfeeding Hepatic, renal, autoimmune, or chronic inflammatory disease
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Premenstrual Syndrome Depression Women who are non-smokers between the ages of 18-45 years (smokers 18-34 years) Regular menstrual cycles (26-34 days in length, predictable within 7 days) for the past 6 months Determination that the antidepressant medication was initiated for the treatment of unipolar major depression, minor depression (depression, not otherwise specified), or dysthymia. Major depression and dysthymia will be evaluated through administration of the Mini-International Neuropsychiatric Interview (MINI). Minor depression will be evaluated by administration of the Structured Clinical Interview for Diagnosis-IV(SCID)10 section J.3 Use of an antidepressant for at least 3 months for treatment of a depressive disorder, with stable dose for at least 2 months. It is acceptable to be on more than one psychiatric medication as long as one of them is an antidepressant Expected continued use of the same antidepressant at the same dose for the duration of the study 30% increase of the mid-follicular phase Montgomery-Åsberg Depression Rating Scale (MADRS) score to the late-luteal phase MADRS will be required for during the tracking phase of the study and will be assessed prospectively over 1 menstrual cycle Normal pelvic exam and PAP smear in the past 12 months Normal TSH at screen if on thyroid medication, must be on a stable dose for 2 months or greater, and have a normal TSH at screen Negative serum HCG at baseline, and negative urine HCG at visits 3 and 5  Amenorrhea or irregular menstrual periods (defined as unable to predict within 7 days) during past 6 months Pregnancy or breastfeeding (serum HCG test administered at baseline study visit, and urine HCG at visits 3 and 5) Current cigarette smoking in women who are older than 34 years Presence of any of the following psychiatric and substance use disorders, based on administration of the MINI at the baseline study visit Any history of mania or hypomania suggesting bipolar disorder Any lifetime history of a psychotic disorder Depression deemed by the physician investigator to be too severe to be treated in the study Use of benzodiazepines or antipsychotic to target premenstrual symptoms Luteal-phase dose adjustment of the antidepressant. Use of a hormone releasing IUD (intrauterine device) Use of an OCP or other systemic hormonal therapies (oral, transdermal or injection preparations of androgens, estrogens, or progestins) in the past 2 months Any contraindication or previous adverse event to any OCP therapy
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Contraception Signed and dated informed consent Age between 18 and 50 years (inclusive), smokers maximum age of 35 years (inclusive) at Visit 1 Otherwise healthy female subjects requesting contraception and currently using a LNG, NGM, or norethindrone/norethindrone acetate containing OC in a 21-day regimen and suffering from at least moderate pelvic pain, headache or both defined by an average of the highest 3 values of >/=35 mm on a VAS during cycle days 22-28 (35 mm VAS is the expected standard deviation of the population VAS reduction) Normal or clinically insignificant cervical smear not requiring further follow up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the last 6 months before screening) Women with atypical squamous cell of undetermined significance (ASCUS) can be included if they have a negative human papilloma virus (HPV) test result. The laboratory will perform an HPV test if the Pap smear result is ASCUS Able to tolerate ibuprofen and willing to use only ibuprofen supplied by the investigator  Pregnancy or lactation (less than three cycles since delivery, abortion, or lactation before start of treatment) Body mass index (BMI) >32 kg/m2 Hypersensitivity to any of the study drug ingredients Individuals not willing to consume pork and beef products. Women may be included if they are willing to take the capsules Safety relevant laboratory values, provided by the central laboratory, outside range before start of treatment Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication (such as but not limited to duodenal ulcers, gastritis, gastrectomy or gastric resection surgery, or renal compromise) Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results Any disease or condition that may worsen under hormonal treatment Undiagnosed abnormal genital bleeding Abuse of alcohol, drugs, or medicines (eg, laxatives)
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Contraception Bleeding Must be of reproductive age from 18 to 45 years Must be choosing LNG-IUC for contraception Must be English-speaking Be willing to avoid additional use of exogenous hormones, such as oral contraceptives, for the duration of the study Be willing to avoid additional use of nonsteroidal antiinflammatory drugs, such as ibuprofen or aspirin for the duration of the study Be willing to comply with the study protocol, keep the bleeding diary and comply with follow-up visits and telephone interviews as scheduled Be willing and able to provide informed consent  Known or suspected pregnancy Contraindication to estrogen use, such as presence or history of venous thromboembolism Arterial thrombosis Thrombophilia disorders, or known family history of Hypertension Migraine headaches with aura or focal neurologic involvement, or any migraine over age 35 years Recent or planned future major surgery which will result in prolonged immobilization during the study period Presence or history of severe hepatic disease or liver tumors Known or suspected estrogen-dependent neoplasm
Patient description: A 38 year old woman complains of severe premenstrual and menstrual pelvic pain, heavy, irregular periods and occasional spotting between periods. Past medical history remarkable for two years of infertility treatment and an ectopic pregnancy at age 26.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Endometriosis Infertility Chronic Pelvic Pain Tubal Ligation A patient who meets all of the following is eligible for the study Premenopausal female 18 to 45 years of age Attending for her first diagnostic laparoscopy or for laparoscopy for tubal sterilisation Has no previous history of endometriosis diagnosis through surgery  A patient who meets any of the following is ineligible for the study Already has a surgically-confirmed diagnosis of endometriosis Aged less than18 or greater than 45 Aged 18-45 but post-menopausal